Tumor Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation.
Despite the therapeutic success of existing HER2 targeted therapies, tumors invariably relapse. This study aimed at identifying new mechanisms responsible for HER2 targeted therapies resistance. We have used a platform of HER2 targeted therapies resistant cell lines and primary cultures of healthy and tumor associated fibroblast to identify new potential targets related to tumor escape from anti-HER2 therapies Results: We have shown that tumor associated fibroblasts (TAFs) promote resistance to HER2-targeted therapies. TAFs produce and secrete high levels of FGF5 that induces FGFR2 activation in the surrounding breast cancer cells. FGFR2 transactivates HER2 via c-Src leading to resistance to HER2 targeted therapies. In vivo, co-inoculating non-resistant cell lines with TAFs results in more aggressive and resistant tumors. Resistant cells activate fibroblasts and secrete FGFR ligands, creating a positive feedback loop that fuels resistance. FGFR2 inhibition not only inhibits HER2 activation, but also induces apoptosis in cells resistant to HER2-targeted therapies. In vivo, inhibitors of FGFR2 reverse resistance and re-sensitize resistant cells to HER2-targeted therapies. In HER2 patients' samples, α-SMA, FGF5 and FGFR2 contribute to poor outcome and correlate with c-Src activation. Importantly, expression of FGF5 and phospho-HER2 correlated with a reduced pathologic complete response rate in patients with HER2 positive breast cancer treated with neoadjuvant trastuzumab which highlights the significant role of TAFs/FGF5 in HER2 breast cancer progression and resistance. We have identified the TAF/FGF5/FGFR2/c-Src/HER2 axis as an escape pathway responsible for HER2 targeted therapies resistance in breast cancer which can be reversed by FGFR inhibitors.